| Literature DB >> 22564344 |
Jane-Francis Tatah Kihla Akoachere1, Suylika Yvonne, Njom Henry Akum, Esemu Nkie Seraphine.
Abstract
BACKGROUND: Urinary tract infection (UTI) represents one of the most common diseases encountered in community medical practice. In resource poor settings, treatment is usually empiric due to the high cost and long duration required for reporting diagnosis by culture and antibiotic susceptibility testing. With the growing problem of drug resistance knowledge of antibiotic susceptibility pattern is pertinent for successful eradication of invading pathogens. Our study, the first of its kind in Cameroon, analyzed the distribution and antibiotic susceptibility of bacteria causing community-acquired urinary tract infection (CAUTI) in two towns (Bamenda and Buea) with a large number of young and middle aged persons, to provide data that could guide empiric treatment.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22564344 PMCID: PMC3528744 DOI: 10.1186/1756-0500-5-219
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Prevalence of infection in study area with respect to gender
| Bamenda (North West) | Females, n = 97 | 65 | 67.0% |
| | Males, n = 53 | 16 | 30.2% |
| 150 | 81 | 54.0% | |
| Buea (South West) | Females, n = 70 | 48 | 68.6% |
| | Males , n =15 | 8 | 53.3% |
| 85 | 56 | 65.9% | |
| Females, n = 167 | 113 | 67.7% | |
| | Males, n = 68 | 24 | 35.3% |
| Males + females = 235 | 137 | 58.3% |
Figure 1Prevalence of bacterial isolates in samples. Ten bacterial species were isolated. E. coli, K. oxytoca and Staph. spp were the predominant pathogens isolated while K. pneumoniae was the least.
Distribution of uropathogens in study sites
| 43 (31.4 ) | Gram-negative n = 101 (73. 7%) | |||
| 24 (29.6) | 11 (19.6) | 35 (25.5) | | |
| 5 (6.2) | 2 (1.8) | 7 (5.1) | | |
| 3 (3.7) | 3 (5.4) | 6 (4.4) | | |
| 4 (4.9) | 0 (0.0)** | 4 (2.9) | | |
| 2 (2.5) | 1 (1.8) | 3 (2.2) | | |
| 1 (1.2) | 1 (1.8) | 2 (1.5) | | |
| 1 (1.2) | 0 (0.0)** | 1 (0.7) | | |
| 18 (22.2) | 15 (26.8) | 33 (24.1) | Gram-positive n = 36 (26.3%) | |
| 0 (0.0)** | 3 (5.4) | 3 (2.2) | | |
*Most prevalent isolate in study site; **Isolated not recovered from study site.
Figure 2Distribution of uropathogens with respect to gender. Prevalence of pathogens was higher in females than in males. All isolates from males were detected in females. C. fruendii, Klebsiella pneumoniae and Serratia marcescens were isolated only from female participants.
Distribution of isolates with respect to age of participants
| 5 (18.5) | 43 (31.4) | ||||
| 17 (21) | 3 (21.4) | 35 (25.5) | |||
| 18 (22.2) | 6 (22.2) | 4 (28.6) | 33 (24.1) | ||
| 1 (6.7) | 4 (4.9) | 1 (3.7) | 1 (7.1) | 7 (5.1) | |
| 0** | 3 (3.7) | 2 (7.4) | 1 (7.1) | 6 (4.4) | |
| 0** | 3 (3.7) | 1 (3.7) | 0** | 4 (2.9) | |
| 0** | 2 (2.5) | 1 (3.7) | 0** | 3 (2.2) | |
| 1 (6.7) | 2 (2.5) | 0** | 0** | 3 (2.2) | |
| 1 (6.7) | 1 (1.2) | 0** | 0** | 2 (1.5) | |
| 0** | 1 (1.2) | 0** | 0** | 1 (0.7) | |
*Most prevalent pathogen in age group; **Pathogen not detected in age group.
Antibiotic susceptibility of isolates from each region (%)
| 93.3 | 26.1 | 100 | 52.2 | 100 | 17.4 | 100 | 39.1 | 80 | 43.5 | 20 | 43.5 | 35 | 65 | |
| 36.4 | 36.4 | 100 | 87.5 | 0 | 0 | 0 | 29.2 | 100 | 91.2 | 90.9 | 83.3 | 18.2 | 75 | |
| 40 | 77.7 | 80 | 55.6 | 0 | 0 | 33.3 | 55.6 | 66.7 | 55.6 | 40 | 66.7 | 53.3 | 72.2 | |
| 100 | 0 | 0 | 80 | 0 | 0 | 100 | 50 | 100 | 80 | 0 | 80 | 100 | 100 | |
| 0 | 66.7 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 66.7 | 66.7 | 100 | |
| ND | 0 | ND | 50 | ND | 0 | ND | 50 | ND | 25 | ND | 50 | ND | 25 | |
| 0 | 50 | 0 | 100 | 0 | 0 | 100 | 0 | 100 | 100 | 0 | 50 | 0 | 50 | |
| 100 | ND | 0 | ND | 0 | ND | 100 | ND | 100 | ND | 0 | ND | 100 | ND | |
| 0 | 0 | 100 | 0 | 0 | 0 | 0 | 100 | 0 | 100 | 0 | 0 | 0 | 0 | |
| ND | 0 | ND | 100 | ND | 0 | ND | 0 | ND | 0 | ND | 0 | ND | 0 | |
BU- Buea; BD-Bamenda; ND-Not determined as isolate was not recovered from study site; AMP-Ampicillin; CIP-Ciprofloxacin; COT-Cotrimoxazole; ERY-Erythromycin; GEN- Gentamicin; NIT- Nitrofurantoin; CEF- Ceftriaxone.